The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
The company is bringing precision therapies for gynaecological cancers
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
cSCC is one of the most common cancers in the U.S. and globally
NewCo’s pipeline includes five investigational medicines
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Subscribe To Our Newsletter & Stay Updated
